
Alessio Aghemo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7632009/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	13.9	1,548
2	EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 2018, 69, 461-511.	1.8	1,489
3	EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology, 2011, 55, 245-264.	1.8	1,083
4	EASL recommendations on treatment of hepatitis C: Final update of the seriesâ~†. Journal of Hepatology, 2020, 73, 1170-1218.	1.8	671
5	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	3.7	370
6	A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology, 2012, 56, 532-543.	3.6	354
7	High rates of 30-day mortality in patients with cirrhosis and COVID-19. Journal of Hepatology, 2020, 73, 1063-1071.	1.8	279
8	COVIDâ€19 and liver disease. Liver International, 2020, 40, 1278-1281.	1.9	252
9	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	3.7	237
10	Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology, 2011, 53, 791-799.	3.6	227
11	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	1.6	193
12	Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C. Gastroenterology, 2010, 138, 108-115.	0.6	190
13	Impact of COVID-19 on global HCV elimination efforts. Journal of Hepatology, 2021, 74, 31-36.	1.8	189
14	EASL Recommendations on Treatment of Hepatitis C 2014. Journal of Hepatology, 2014, 61, 373-395.	1.8	172
15	Treatment With Ledipasvir–Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection. Annals of Internal Medicine, 2017, 166, 109.	2.0	164
16	Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 2015, 26, 1028-1038.	1.6	159
17	Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. Journal of Clinical Medicine, 2020, 9, 1548.	1.0	147
18	New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology, 2013, 58, 428-438.	3.6	142

#	Article	IF	CITATIONS
19	The diagnostic accuracy of Fibroscan® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. Journal of Hepatology, 2013, 59, 251-256.	1.8	131
20	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: TableÂ1. Gut, 2015, 64, 1824-1833.	6.1	128
21	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology and Hepatology, 2018, 3, 125-133.	3.7	128
22	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology, 2010, 52, 249-255.	3.6	123
23	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology, 2021, 160, 2435-2450.e34.	0.6	118
24	Genetic variation in the <i>interleukin</i> - <i>28B</i> gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology, 2011, 54, 1127-1134.	3.6	115
25	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of Hepatology, 2019, 70, 379-387.	1.8	109
26	Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1460-1466.	3.3	106
27	Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3187-3197.	3.3	106
28	Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. Journal of Hepatology, 2016, 64, 1217-1223.	1.8	104
29	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Internal and Emergency Medicine, 2012, 7, 139-144.	1.0	96
30	Role of liver biopsy in hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 6041-6052.	1.4	92
31	A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clinical Therapeutics, 2010, 32, 2117-2138.	1.1	87
32	Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy, 2012, 12, 193-207.	1.4	85
33	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	1.6	85
34	Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology, 2012, 56, 1681-1687.	3.6	83
35	Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart, 2020, 106, 1512-1518.	1.2	82
36	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology, 2012, 55, 336-342.	3.6	81

#	Article	IF	CITATIONS
37	Direct-acting antivirals: the endgame for hepatitis C?. Current Opinion in Virology, 2017, 24, 31-37.	2.6	81
38	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 1183-1191.e7.	2.4	79
39	The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology, 2018, 69, 1188-1196.	1.8	78
40	Disease burden and economic impact of diagnosed nonâ€alcoholic steatohepatitis in five European countries in 2018: A costâ€ofâ€ilness analysis. Liver International, 2021, 41, 1227-1242.	1.9	76
41	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Journal of Autoimmunity, 2020, 114, 102511.	3.0	72
42	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. Journal of Hepatology, 2009, 50, 916-922.	1.8	69
43	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. Journal of Hepatology, 2019, 71, 1106-1115.	1.8	69
44	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation. Hepatology, 2010, 52, 1723-1730.	3.6	67
45	Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 485-494.	8.2	62
46	Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. Journal of Hepatology, 2015, 63, 1484-1490.	1.8	61
47	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Nutrients, 2019, 11, 2971.	1.7	57
48	Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis. Journal of Viral Hepatitis, 2014, 21, 90-98.	1.0	56
49	Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. Liver Cancer, 2020, 9, 15-27.	4.2	56
50	Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?. Liver International, 2017, 37, 950-962.	1.9	55
51	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. Digestive and Liver Disease, 2020, 52, 937-941.	0.4	53
52	Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. Journal of Hepatology, 2013, 59, 38-44.	1.8	52
53	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology, 2015, 62, 111-117.	3.6	52
54	Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 412-414.	1.4	51

#	Article	IF	CITATIONS
55	Management of patients with autoimmune liver disease during COVID-19 pandemic. Journal of Hepatology, 2020, 73, 453-455.	1.8	51
56	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. Clinical Gastroenterology and Hepatology, 2020, 18, 2366-2368.e3.	2.4	51
57	Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. Gut, 2016, 65, 1998-2006.	6.1	50
58	COVIDâ€19â€induced endotheliitis: emerging evidence and possible therapeutic strategies. British Journal of Haematology, 2021, 193, 43-51.	1.2	49
59	The Course of Esophageal Varices in Patients with Hepatitis C Cirrhosis Responding to Interferon/ Ribavirin Therapy. Antiviral Therapy, 2011, 16, 677-684.	0.6	48
60	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Digestive and Liver Disease, 2019, 51, 310-317.	0.4	47
61	Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network. European Review for Medical and Pharmacological Sciences, 2016, 20, 17-19.	0.5	47
62	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	1.4	46
63	Management of hepatitis C virus infection in the Asia-Pacific region: an update. The Lancet Gastroenterology and Hepatology, 2017, 2, 52-62.	3.7	45
64	Hepatitis C treatment in patients with kidney disease. Kidney International, 2013, 84, 874-879.	2.6	41
65	Short-term health-related quality of life, physical function and psychological consequences of severe COVID-19. Annals of Intensive Care, 2021, 11, 91.	2.2	41
66	Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. Journal of Hepatology, 2014, 60, 913-919.	1.8	39
67	Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. Digestive and Liver Disease, 2014, 46, 152-156.	0.4	38
68	Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience. Gut, 2020, 69, 981-983.	6.1	38
69	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Digestive and Liver Disease, 2022, 54, 452-460.	0.4	38
70	Liver tests abnormalities in COVID-19: trick or treat?. Journal of Hepatology, 2020, 73, 1275-1276.	1.8	37
71	Implications of <i><scp>PNPLA</scp>3</i> polymorphism in chronic hepatitis <scp>C</scp> patients receiving peginterferon plus ribavirin. Alimentary Pharmacology and Therapeutics, 2012, 35, 1434-1442.	1.9	35
72	Transarterial chemoembolization with drugâ€eluting beads is effective for the maintenance of the Milanâ€in status in patients with a small hepatocellular carcinoma. Liver Transplantation, 2015, 21, 1259-1269.	1.3	35

#	Article	IF	CITATIONS
73	Liver stiffness measurement reliability and main determinants of point shearâ€wave elastography in patients with chronic liver disease. Alimentary Pharmacology and Therapeutics, 2016, 44, 356-365.	1.9	35
74	Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology, 2016, 14, 1331-1336.	2.4	34
75	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virusâ€related cirrhosis who attained sustained virological response. Liver International, 2017, 37, 1526-1534.	1.9	34
76	High mortality in COVIDâ€19 patients with mild respiratory disease. European Journal of Clinical Investigation, 2020, 50, e13314.	1.7	34
77	COVIDâ€19 and the liver: A 2021 update. Liver International, 2021, 41, 1988-1998.	1.9	34
78	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. Journal of Autoimmunity, 2019, 100, 17-26.	3.0	33
79	Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. Journal of Viral Hepatitis, 2013, 20, 858-866.	1.0	32
80	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. Journal of Gastrointestinal Surgery, 2019, 23, 2216-2224.	0.9	32
81	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology, 2016, 63, 418-427.	3.6	31
82	The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antiviral Therapy, 2009, 14, 577-584.	0.6	30
83	The case for simplifying and using absolute targets for viral hepatitis elimination goals. Journal of Viral Hepatitis, 2021, 28, 12-19.	1.0	28
84	Is there an â€~ideal' diet for patients with NAFLD?. European Journal of Clinical Investigation, 2022, 52, e13659.	1.7	28
85	Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense. Journal of Hepatology, 2012, 57, 1326-1335.	1.8	27
86	Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Seminars in Immunopathology, 2013, 35, 111-120.	2.8	27
87	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. PLoS ONE, 2020, 15, e0232371.	1.1	27
88	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. Journal of Hepatology, 2009, 51, 288-295.	1.8	26
89	Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials. Digestive and Liver Disease, 2013, 45, 1-7.	0.4	26
90	Interferon–ribavirin therapy induces serum antibodies determining â€~rods and rings' pattern in hepatitis C patients. Journal of Viral Hepatitis, 2014, 21, 944-949.	1.0	26

#	Article	IF	CITATIONS
91	High efficacy of directâ€acting antiâ€viral agents in hepatitis C virusâ€infected cirrhotic patients with successfully treated hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2018, 47, 1705-1712.	1.9	26
92	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 2021, 74, 801-810.	1.8	26
93	Bridging all oral <scp>DAA</scp> therapy from wait time to postâ€liver transplant to improve <scp>HCV</scp> eradication?. Liver International, 2015, 35, 1-4.	1.9	25
94	Recovery after l-DOPA treatment in peginterferon and ribavirin induced parkinsonism. European Journal of Internal Medicine, 2008, 19, 370-371.	1.0	24
95	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. Digestive and Liver Disease, 2013, 45, 43-49.	0.4	23
96	Hepatorenal Syndrome and Novel Advances in its Management. Kidney and Blood Pressure Research, 2013, 37, 588-601.	0.9	23
97	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS ONE, 2016, 11, e0155967.	1.1	23
98	Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepatic Medicine: Evidence and Research, 2014, 6, 25.	0.9	22
99	Sofosbuvirâ€based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. Liver International, 2016, 36, 1585-1589.	1.9	22
100	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to <scp>IFN</scp> and cirrhosis regression. Liver International, 2018, 38, 1459-1467.	1.9	22
101	Adherence to panâ€genotypic glecaprevir/pibrentasvir and efficacy in HCVâ€infected patients: A pooled analysis of clinical trials. Liver International, 2020, 40, 778-786.	1.9	22
102	Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. Journal of Hepatology, 2012, 56, 341-347.	1.8	21
103	The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy. International Journal of Cardiology, 2021, 324, 249-254.	0.8	21
104	Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. Digestive and Liver Disease, 2022, 54, 237-242.	0.4	20
105	Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients. Med, 2021, 2, 435-447.e4.	2.2	20
106	Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C. Expert Review of Anti-Infective Therapy, 2009, 7, 925-935.	2.0	19
107	The Association of Il28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent. International Journal of Molecular Sciences, 2014, 15, 7213-7224.	1.8	19
108	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Digestive and Liver Disease, 2017, 49, 731-741.	0.4	19

#	Article	IF	CITATIONS
109	Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clinics in Liver Disease, 2017, 21, 631-643.	1.0	19
110	US Features of Liver Surface Nodularity as a Predictor of Severe Fibrosis in Chronic Hepatitis C. Radiology, 2005, 234, 641-641.	3.6	18
111	HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C. Journal of Hepatology, 2009, 51, 964-966.	1.8	18
112	Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. Journal of Hepatology, 2012, 56, 1209-1210.	1.8	18
113	Telaprevir in a Patient with Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis. Antiviral Therapy, 2014, 19, 527-531.	0.6	18
114	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver International, 2017, 37, 1295-1303.	1.9	18
115	Evaluation of three "beyond Baveno Vl―criteria to safely spare endoscopies in compensated advanced chronic liver disease. Digestive and Liver Disease, 2019, 51, 1135-1140.	0.4	18
116	Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. World Journal of Gastroenterology, 2013, 19, 1359.	1.4	18
117	Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis. American Journal of Gastroenterology, 2008, 103, 1966-1972.	0.2	17
118	Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations. Techniques and Innovations in Gastrointestinal Endoscopy, 2021, 23, 179-189.	0.4	17
119	Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements. Liver International, 2021, 41, 649-655.	1.9	16
120	Virtual Biopsy for Diagnosis of Chemotherapy-Associated Liver Injuries and Steatohepatitis: A Combined Radiomic and Clinical Model in Patients with Colorectal Liver Metastases. Cancers, 2021, 13, 3077.	1.7	16
121	The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antiviral Therapy, 2009, 14, 577-84.	0.6	16
122	The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. Antiviral Therapy, 2009, 14, 789-796.	0.6	15
123	Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opinion on Biological Therapy, 2011, 11, 301-313.	1.4	15
124	PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Review of Anti-Infective Therapy, 2013, 11, 459-474.	2.0	15
125	Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. Journal of Hepatology, 2017, 66, S95-S96.	1.8	15
126	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15

#	Article	IF	CITATIONS
127	Comparison of three therapeutic regimens for genotypeâ€3 hepatitis C virus infection in a large realâ€life multicentre cohort. Liver International, 2020, 40, 769-777.	1.9	15
128	Return to Work After Coronavirus Disease 2019 Acute Respiratory Distress Syndrome and Intensive Care Admission: Prospective, Case Series at 6 Months From Hospital Discharge*. Critical Care Medicine, 2021, 49, e1157-e1162.	0.4	15
129	Impaired Response to Interferon-α2B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection. Antiviral Therapy, 2006, 11, 797-802.	0.6	15
130	How to optimize HCV therapy in genotype 2 patients. Liver International, 2013, 33, 35-40.	1.9	14
131	Ledipasvir/Sofosbuvir for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 Hcv Infection. Journal of Hepatology, 2016, 64, S183.	1.8	14
132	Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. PLoS ONE, 2015, 10, e0138546.	1.1	14
133	Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir. PLoS ONE, 2014, 9, e95881.	1.1	13
134	Estimating <scp>HCV</scp> disease burden – volume 3 (editorial). Journal of Viral Hepatitis, 2015, 22, 1-3.	1.0	13
135	Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1373-1383.	1.4	13
136	From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease, 2016, 48, 995-1005.	0.4	13
137	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. Journal of Antimicrobial Chemotherapy, 2016, 71, 739-750.	1.3	13
138	High rate of sustained virological response with directâ€acting antivirals in haemophiliacs with HCV infection: A multicenter study. Liver International, 2020, 40, 1062-1068.	1.9	13
139	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. Digestive and Liver Disease, 2021, 53, 677-681.	0.4	13
140	Management of liver disease in Italy after one year of the SARS oVâ€2 pandemic: A webâ€based survey. Liver International, 2021, 41, 2228-2232.	1.9	13
141	Acute Tubular Necrosis Following Interferon-Based Therapy for Hepatitis C: Case Study with Literature Review. Kidney and Blood Pressure Research, 2013, 38, 52-60.	0.9	12
142	Treatment of patients with dual hepatitis B and C: a step in the right direction. Gut, 2014, 63, 380-381.	6.1	12
143	Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better. Gastroenterology, 2015, 148, 13-16.	0.6	12
144	The quest for safe and effective treatments of chronic hepatitis <scp>C</scp> in patients with kidney impairment. Liver International, 2016, 36, 791-793.	1.9	12

#	Article	IF	CITATIONS
145	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Digestive and Liver Disease, 2020, 52, 190-198.	0.4	12
146	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3â€infected patients within the Italian network VIRONETâ€C. Liver International, 2021, 41, 1802-1814.	1.9	12
147	Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2007, 14, 070901052026003-???.	1.0	11
148	Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepatitis Monthly, 2012, 12, 411-414.	0.1	11
149	Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis <scp>C</scp> patients. Journal of Viral Hepatitis, 2014, 21, 416-423.	1.0	11
150	Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. Journal of Clinical Virology, 2014, 59, 274-275.	1.6	11
151	Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma—a composite scenario. Hepatobiliary Surgery and Nutrition, 2018, 7, 130-133.	0.7	11
152	A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. Current Medical Research and Opinion, 2021, 37, 917-927.	0.9	11
153	Real-World Outcomes in Historically Underserved Patients with Chronic HepatitisÂC Infection Treated with Glecaprevir/Pibrentasvir. Infectious Diseases and Therapy, 2021, 10, 2203-2222.	1.8	11
154	Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a. Hepatitis Monthly, 2011, 11, 918-924.	0.1	10
155	What do clinicians need to watch for with directâ€acting antiviral therapy?. Journal of the International AIDS Society, 2018, 21, e25076.	1.2	10
156	Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report. Hepatology Communications, 2018, 2, 1179-1183.	2.0	10
157	Safety of vedolizumab in liver transplant recipients: A systematic review. United European Gastroenterology Journal, 2019, 7, 875-880.	1.6	10
158	Reply to: Correspondence on "High rates of 30-day mortality in patients with cirrhosis and COVID-19― Journal of Hepatology, 2020, 73, 1570-1571.	1.8	10
159	Letter to the Editor: Clinical Management of Nonrespiratory Diseases in the COVID-19 Pandemic: What Have We Done and What Needs to Be Done?. Telemedicine Journal and E-Health, 2020, 26, 1206-1208.	1.6	10
160	Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure. Clinical and Molecular Hepatology, 2019, 25, 360-365.	4.5	10
161	Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. Hepatology, 2010, 52, 1170-1171.	3.6	9
162	Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks. Hepatitis Monthly, 2012, 12, 361-368.	0.1	9

#	Article	IF	CITATIONS
163	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2014, 46, 18-24.	0.4	9
164	Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. Expert Opinion on Drug Safety, 2015, 14, 473-484.	1.0	9
165	Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. Updates in Surgery, 2020, 72, 413-421.	0.9	9
166	Interaction between PNPLA3 1148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS ONE, 2014, 9, e106022.	1.1	9
167	Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. Viruses, 2022, 14, 1096.	1.5	9
168	HepatitisÃ,ÂC virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. Journal of Thrombosis and Haemostasis, 2009, 7, 1997-2005.	1.9	8
169	Clinical drivers in naÃ⁻ve patient eligibility for treatment of chronic hepatitis C. Journal of Viral Hepatitis, 2012, 19, 3-6.	1.0	8
170	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naÃ⁻ve patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2014, 46, 818-825.	0.4	8
171	Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study. Journal of Hepatology, 2018, 68, S65.	1.8	8
172	Real life experiences in HCV management in 2018. Expert Review of Anti-Infective Therapy, 2019, 17, 117-128.	2.0	8
173	Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. Liver International, 2022, 42, 26-37.	1.9	8
174	Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients. Digestive and Liver Disease, 2021, 53, 1232-1234.	0.4	8
175	The Prevalence, Clinical Features and Response to Antiviral Therapy of Patients with Chronic Hepatitis C who are Seropositive for Liver–Kidney Microsome Type 1 Antibodies. Antiviral Therapy, 2005, 10, 715-720.	0.6	8
176	Lack of Rapid Virological Response Predicts Interferon-α2b/Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study. Antiviral Therapy, 2007, 12, 1033-1040.	0.6	8
177	HBV and HCV Therapy. Viruses, 2009, 1, 484-509.	1.5	7
178	Cirrhosis Regression in Chronic Hepatitis C: An Old Tale With a New Ending. Gastroenterology, 2009, 136, 1447-1449.	0.6	7
179	Peginterferon Alfa-2B Versus Peginterferon Alfa-2A With Ribavirin for the Treatment of Chronic Hepatitis C: The Pursuit of an Ideal. Gastroenterology, 2010, 138, 386-389.	0.6	7
180	Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C. Journal of Viral Hepatitis, 2012, 19, 37-41.	1.0	7

#	Article	IF	CITATIONS
181	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65Âyears with HCV genotype 1 cirrhosis. Infection, 2018, 46, 607-615.	2.3	7
182	Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. Hepatitis Monthly, 2011, 11, 918-924.	0.1	7
183	Eukaryotic initiation factor 5B: A new player for the anti-hepatitis C virus effect of ribavirin?. Medical Hypotheses, 2012, 79, 471-473.	0.8	6
184	Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. Thrombosis and Haemostasis, 2014, 111, 1067-1076.	1.8	6
185	Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients. Antiviral Therapy, 2014, 19, 747-753.	0.6	6
186	Daclatasvir for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy, 2015, 16, 2679-2688.	0.9	6
187	Hepatitis C Therapy: Game Over!. Gastroenterology, 2016, 151, 795-798.	0.6	6
188	Screening of oesophagogastric varices in virus-related compensated advanced chronic liver disease: Beyond the Baveno VI criteria. Digestive and Liver Disease, 2017, 49, e38.	0.4	6
189	Immunosuppressive and antiviral treatment of hepatitis C virus–associated glomerular disease: A long-term follow-up. International Journal of Artificial Organs, 2018, 41, 306-318.	0.7	6
190	JNJâ€4178 (ALâ€335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virusâ€Infected Patients Without Cirrhosis: OMEGAâ€1. Hepatology, 2019, 69, 2349-2363.	3.6	6
191	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Digestive and Liver Disease, 2021, 53, 612-619.	0.4	6
192	Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center. Cancers, 2021, 13, 2070.	1.7	6
193	Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?. Viruses, 2021, 13, 1048.	1.5	6
194	Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver International, 2021, 41, 1441-1442.	1.9	6
195	Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit. PLoS ONE, 2016, 11, e0164452.	1.1	6
196	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Realâ€Life Cohort Study. Hepatology Communications, 2022, 6, 867-877.	2.0	6
197	Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antiviral Therapy, 2006, 11, 797-802.	0.6	6
198	Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-NaÃ ⁻ ve Patients with Compensated Cirrhosis: The CREST Study. Advances in Therapy, 2022, 39, 3146-3158.	1.3	6

#	Article	IF	CITATIONS
199	Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens. Journal of Hepatology, 2012, 56, 276-278.	1.8	5
200	Selection of Resistant–Associated Variants to the NS5A Inhibitor Daclatasvir: Revenge of the Hepatitis C Virus. Gastroenterology, 2013, 145, 247-249.	0.6	5
201	De Novo Membrano-Proliferative Nephritis Following Interferon Therapy for Chronic Hepatitis C (Case Study and Literature Review). Digestive Diseases and Sciences, 2014, 59, 691-695.	1.1	5
202	P1032 LOW ACCURACY OF NON-INVASIVE TESTS FOR ASSESSING RESIDUAL CIRRHOSIS IN HEPATITIS C PATIENTS WITH A SUSTAINED VIROLOGICAL RESPONSE. Journal of Hepatology, 2014, 60, S418-S419.	1.8	5
203	Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C― Journal of Hepatology, 2015, 63, 1535-1536.	1.8	5
204	Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut, 2015, 64, 860-862.	6.1	5
205	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Digestive and Liver Disease. 2018. 50. 1133-1152.	0.4	5
206	Sarcopenia in chronic liver disease: easy to diagnose but hard to treat. Liver International, 2020, 40, 2627-2629.	1.9	5
207	The effect of COVID-19 epidemic on vital signs in hospitalized patients: a pre-post heat-map study from a large teaching hospital. Journal of Clinical Monitoring and Computing, 2022, 36, 829-837.	0.7	5
208	Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges. World Journal of Gastroenterology, 2022, 28, 1430-1443.	1.4	5
209	Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 455-464.	0.7	4
210	Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals?. Journal of Hepatology, 2015, 63, 1294.	1.8	4
211	Postsustained Virological Response Management in Hepatitis C Patients. Seminars in Liver Disease, 2020, 40, 233-239.	1.8	4
212	Critical Care Outreach Team During COVID-19: Ventilatory Support in the Ward and Outcomes. Respiratory Care, 2021, 66, 928-935.	0.8	4
213	Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. Expert Opinion on Drug Safety, 2021, 20, 839-843.	1.0	4
214	What gastroenterologists should know about SARS–CoV 2 vaccine: World Endoscopy Organization perspective. United European Gastroenterology Journal, 2021, 9, 787-796.	1.6	4
215	High prevalence of portoâ€sinusoidal vascular disease in patients with constantly elevated gammaâ€glutamyl transferase levels. Liver International, 2022, 42, 1692-1695.	1.9	4
216	HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist. Journal of Hepatology, 2022, , .	1.8	4

#	Article	IF	CITATIONS
217	Genetic Variation in Interleukin-28B Predicts Hepatitis C Treatment-Induced Viral Clearance in Genotype 1 Patients: The Dawn of a New Era?. Gastroenterology, 2010, 138, 2546-2549.	0.6	3
218	Telaprevir for Hepatitis C Re-treatment: An Open Door on a Long and Winding Road. Gastroenterology, 2010, 139, 1412-1416.	0.6	3
219	291 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY. Journal of Hepatology, 2010, 52, S122.	1.8	3
220	1318 FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C IS NOT INFLUENCED BY IL28B POLYMORPHISMS. Journal of Hepatology, 2011, 54, S519.	1.8	3
221	Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. Journal of Virological Methods, 2013, 187, 271-273.	1.0	3
222	Is there need for more than one IL28B single nucleotide polymorphism in hepatitis C clinical practice?. Hepatology, 2013, 57, 416-416.	3.6	3
223	Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. BioMed Research International, 2013, 2013, 1-6.	0.9	3
224	Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders. Hepatology, 2013, 57, 2087-2087.	3.6	3
225	Second wave antiâ€ <scp>HCV</scp> protease inhibitors: too little too late?. Liver International, 2014, 34, e168-70.	1.9	3
226	High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. Clinical Microbiology and Infection, 2014, 20, O936-O938.	2.8	3
227	Screening and surveillance of esophageal varices: Validation of Baveno VI criteria in a cohort of cirrhotic HCV patients. Digestive and Liver Disease, 2016, 48, e17.	0.4	3
228	Glecaprevir/Pibrentasvir: TheÂFinal Piece in the Hepatitis C Virus Treatment Puzzle?. Gastroenterology, 2018, 154, 1195-1196.	0.6	3
229	Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy. Medicine (United States), 2018, 97, e11307.	0.4	3
230	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Journal of Nephrology, 2018, 31, 685-712.	0.9	3
231	Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3 year study. Journal of Hepatology, 2018, 68, S529.	1.8	3
232	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCVâ€infected patients treated in a realâ€life setting. Journal of Viral Hepatitis, 2021, 28, 558-568.	1.0	3
233	Safety of current antiviral drugs for chronic hepatitis B. Expert Opinion on Drug Safety, 2022, 21, 939-945.	1.0	3
234	The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 2006, 44, 825.	1.8	2

#	Article	IF	CITATIONS
235	The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more?. Hepatology, 2009, 49, n/a-n/a.	3.6	2
236	794 PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS: CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2009, 50, S290-S291.	1.8	2
237	T-29 Early NK cell activation predicts successful treatment outcome in chronic HCV infection. Digestive and Liver Disease, 2011, 43, S86.	0.4	2
238	A 13-Day, Interferon-Free Regimen for Chronic Hepatitis C Genotype 1 Patients: Between Fear and Hope. Gastroenterology, 2011, 141, 396-399.	0.6	2
239	934 DIFFERENCES IN HCV GENOTYPE 1 RVR RATES AMONG CLINICAL TRIALS IN EUROPE DEPEND ON HCV RNA ASSAY SENSITIVITY. Journal of Hepatology, 2012, 56, S364.	1.8	2
240	Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients. Journal of Hepatology, 2012, 56, 1422.	1.8	2
241	Interferon-Free Oral Therapy for Hepatitis C: "Faraway, so Close!― Gastroenterology, 2012, 142, 1253-1254.	0.6	2
242	506 UNDETECTABLE HCV-RNA IN TELAPREVIR-TREATED PATIENTS: LOW CONCORDANCE BETWEEN TWO HIGHLY SENSITIVE REAL-TIME PCR ASSAYS. Journal of Hepatology, 2013, 58, S208.	1.8	2
243	Treatment of chronic hepatitis C with pegylated interferonâ€Î± inÂa patient with recurrent autoimmune thrombotic thrombocytopenic purpura. Transfusion Medicine, 2013, 23, 66-68.	0.5	2
244	Predictors of Psychopathological Outcome During Peg-Interferon and Ribavirin Therapy in Patients with Chronic HCV-Correlated Hepatitis. Journal of Interferon and Cytokine Research, 2013, 33, 9-14.	0.5	2
245	Acute Allograft Rejection following Interferon Therapy for Hepatitis C in Recipients who have Returned to Dialysis after Kidney Transplant Failure: Case Study. International Journal of Artificial Organs, 2014, 37, 803-808.	0.7	2
246	Hepatitis C Genotype 3: A Tough Match for Interferon-Free Regimens. Gastroenterology, 2014, 146, 1125-1127.	0.6	2
247	No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?. Gastroenterology, 2016, 150, 1241-1243.	0.6	2
248	Genotype 3 infection in DAA era: Reports of a real life Northern Italy Network for viral hepatitis after 2 years by the start. Digestive and Liver Disease, 2017, 49, e68.	0.4	2
249	Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: A single-center experience. Digestive and Liver Disease, 2018, 50, 41.	0.4	2
250	Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. Hepatobiliary and Pancreatic Diseases International, 2018, 17, 570-574.	0.6	2
251	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN), Internal and Emergency Medicine, 2018, 13, 1139-1166.	1.0	2
252	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study. Journal of Hepatology, 2018, 68, S86.	1.8	2

#	Article	IF	CITATIONS
253	Screening of esophagogastric varices: Performance of the "Expanded Baveno Vi criteria―and the "platelet 150/MELD 6―strategy in all etiology compensated advanced chronic liver disease. Journal of Hepatology, 2018, 68, S734-S735.	1.8	2
254	Liver International: Anticipating the future of hepatology worldwide. Liver International, 2019, 39, 1796-1797.	1.9	2
255	Micro-elimination of hepatitis C virus infection in β-Thalassaemia major patients: Positively moving towards the World Health Organisation 2030 eradication goal. Digestive and Liver Disease, 2019, 51, 568-569.	0.4	2
256	HCV screening: Moving from theory to practice. Liver International, 2020, 40, 1538-1540.	1.9	2
257	The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries. Digestive and Liver Disease, 2020, 52, e33-e34.	0.4	2
258	Sofosbuvir in HCV patients with chronic kidney disease: No time for caution. Liver International, 2021, 41, 646-648.	1.9	2
259	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.4	2
260	Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization. Applied Sciences (Switzerland), 2021, 11, 9342.	1.3	2
261	Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antiviral Therapy, 2007, 12, 1033-40.	0.6	2
262	Cost Analysis of Platelet Transfusion in Italy for Patients with Chronic Liver Disease and Associated Thrombocytopenia Undergoing Elective Procedures. ClinicoEconomics and Outcomes Research, 2022, Volume 14, 205-220.	0.7	2
263	Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. Commentary. Annali Dell'Istituto Superiore Di Sanita, 2021, 57, 201-204.	0.2	2
264	A Rapid Point-of-Care Test for the Diagnosis of HCV Infection: Tipping the Balance to Screening Extension Beyond High Risk Populations?. Gastroenterology, 2011, 140, 1347-1349.	0.6	1
265	Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. Biologics: Targets and Therapy, 2012, 6, 363.	3.0	1
266	Understanding the Role of PNPLA3 Genetic Variants in Patients with Chronic Hepatitis C Infection. Digestive Diseases and Sciences, 2012, 57, 1977-1979.	1.1	1
267	Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2013, 38, 553-554.	1.9	1
268	P744 DEPDC5 GENE LOCUS ASSOCIATES WITH SEVERE LIVER FIBROSIS IN INDIVIDUALS WITH CHRONIC HCV INFECTION. Journal of Hepatology, 2014, 60, S318.	1.8	1
269	Cost Analysis of Residual Viremia Detected by Two Real-Time Pcr Assays For Response-Guided (Dual Or) Tj ETQq1	1 0.7843 0.1	14 rgBT /Ov
270	P0750 : Enhanced liver fibrosis (ELF) test does not predict residual cirrhosis after a sustained virological response to hepatitis C treatment. Journal of Hepatology, 2015, 62, S610.	1.8	1

#	Article	IF	CITATIONS
271	Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: A single-center prospective 3-year study. Digestive and Liver Disease, 2018, 50, 36.	0.4	1
272	Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage. Viral Immunology, 2018, 31, 358-361.	0.6	1
273	Screening of esophagogastric varices: Performance of the "Expanded Baveno VI criteria―and the "platelet 150/MELD 6―strategy in all etiology compensated advanced chronic liver disease. Digestive and Liver Disease, 2018, 50, 59.	0.4	1
274	No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals. Liver International, 2018, 38, 2342.	1.9	1
275	Managing Patients With Nonalcoholic Fatty Liver Disease: Is It Really Only About Fibrosis?. Gastroenterology, 2018, 155, 926-928.	0.6	1
276	THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy. Journal of Hepatology, 2019, 70, e234-e235.	1.8	1
277	THU-180-Treatment of genotype 3 HCV infection in the large real-life "Navigatore Lombardia― multicentre cohort: Results from three different regimens. Journal of Hepatology, 2019, 70, e241.	1.8	1
278	THU-131-Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks. Journal of Hepatology, 2019, 70, e217.	1.8	1
279	THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients. Journal of Hepatology, 2019, 70, e223-e224.	1.8	1
280	Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. The Lancet Gastroenterology and Hepatology, 2019, 4, 5-6.	3.7	1
281	All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 51-53.	2.4	1
282	Do gammaâ€glutamyltransferase levels identify HCV patients who require lifelong post‣VR followâ€up?. Liver International, 2020, 40, 509-510.	1.9	1
283	High prevalence of multidrugâ€resistant bacteria in patients with pyogenic liver abscess following liver cancer locoâ€regional treatments. Liver International, 2021, 41, 1909-1912.	1.9	1
284	Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma Journal of Clinical Oncology, 2019, 37, 341-341.	0.8	1
285	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. Blood, 2020, 136, 6-8.	0.6	1
286	Serum nuclear autoantibodies with nucleolar pattern in chronic liver diseases. Digestive and Liver Disease, 2006, 38, A77.	0.4	0
287	The Role of Hepatic Venous Pressure Gradient in Hepatitis C Virus Compensated Cirrhosis. Gastroenterology, 2007, 133, 2076.	0.6	0
288	Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients. Digestive and Liver Disease, 2007, 39, A39.	0.4	0

#	Article	IF	CITATIONS
289	Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?. Journal of Viral Hepatitis, 2008, 15, 471-471.	1.0	0
290	OC3.04.6 LIVER CELL PROLIFERATION AND LIVER CANCER RISK IN PATIENTS WITH HEPATITIS C VIRUS-RELATED CIRRHOSIS UNDER ANTIVIRAL TREATMENT. Digestive and Liver Disease, 2008, 40, S47.	0.4	0
291	PA.103 LOW RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH CHRONIC HEPATITIS C AND CONCURRENT INACTIVE HEPATITIS B INFECTION TREATED WITH INTERFERON AND RIBAVIRIN. Digestive and Liver Disease, 2008, 40, S112.	0.4	0
292	PA.106 HEPATITIS C VIRUS GENOTYPES AND PATTERNS OF PEGINTERFERON ALFA-2B/RIBAVIRIN TREATMENT FAILURE IN PATIENTS WITH CIRRHOSIS: A SINGLE CENTER STUDY OF 471 NAÃVE PATIENTS. Digestive and Liver Disease, 2008, 40, S113-S114.	0.4	0
293	Cirrhosis Regression in Chronic Hepatitis C: An Old Tale With a New Ending. Gastroenterology, 2009, 136, 1114-1116.	0.6	Ο
294	Treatment of Nonresponder Patients With Chronic Hepatitis C: To Repeat or Not to Repeat? That Is the Question. Gastroenterology, 2009, 137, 1521-1524.	0.6	0
295	594 ERYTHROID DIFFERENTIATION IS SUPPRESSED BY RIBAVIRIN DURING COMBINATION THERAPY WITH PEGYLATED INTERFERON-α2a IN CHRONIC HEPATITIS C: AN IN VITRO AND IN VIVO STUDY. Journal of Hepatology, 2009, 50, S218.	1.8	0
296	P.130 SAFETY AND EFFICACY OF PEG-IFN/RBV THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND HIGH TITRES OF SERUM AUTOANTIBODIES: A SUB-ANALYSIS OF THE MIST STUDY. Digestive and Liver Disease, 2010, 42, S149.	0.4	0
297	P.140 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. Digestive and Liver Disease, 2010, 42, S152.	0.4	0
298	P.142 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND (US). Digestive and Liver Disease, 2010, 42, S153.	0.4	0
299	6 EPIDEMIOLOGICAL CHANGES OF BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: A CURRENT CLINICAL PROBLEM. Digestive and Liver Disease, 2010, 42, S3.	0.4	0
300	35 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND (US). Digestive and Liver Disease, 2010, 42, S14.	0.4	0
301	T.N.38 SAFETY AND EFFICACY OF PEG-IFN/RBV THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND HIGH TITRES OF SERUM AUTOANTIBODIES: A SUB-ANALYSIS OF THE MIST STUDY. Digestive and Liver Disease, 2010, 42, S28.	0.4	0
302	F.N.20 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. Digestive and Liver Disease, 2010, 42, S40.	0.4	0
303	F.N.29 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY. Digestive and Liver Disease, 2010, 42, S44.	0.4	0
304	194 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND. Journal of Hepatology, 2010, 52, S84.	1.8	0
305	229 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. Journal of Hepatology, 2010, 52, S97.	1.8	0
306	1148 THE PRESENCE OF HEPATITIS C VIRUS DELETION MUTANTS IN CHRONIC HEPATITIS C PATIENTS AND THEIR ROLE DURING PEG-IFN/RIBAVIRIN THERAPY IN HCV-1 PATIENTS. Journal of Hepatology, 2011, 54, S453-S454.	1.8	0

#	Article	IF	CITATIONS
307	OC-9 The presence of hepatitis C virus deletion mutants in chronic hepatitis C patients and their role during PEG-IFN/ribavirin therapy. Digestive and Liver Disease, 2011, 43, S68.	0.4	0
308	T-37 Distribution of the IL28B rs12979860 polymorphism and its influence on sustained virological response rates in the MIST trial. Digestive and Liver Disease, 2011, 43, S88.	0.4	0
309	T-42 A sustained virological response to interferon prevents insulin resistance in chronic hepatitis C patients. Digestive and Liver Disease, 2011, 43, S90.	0.4	0
310	303 EARLY ACTIVATION OF EFFECTOR CYTOTOXIC NK CELLS PREDICTS SUCCESSFUL TREATMENT OUTCOME IN CHRONIC HCV INFECTION. Journal of Hepatology, 2011, 54, S123.	1.8	0
311	46 IMMUNOLOGICAL PROFILES OF NON-RESPONDER AND RELAPSER PATIENTS WITH CHRONIC HCV INFECTION TREATED WITH STANDARD OF CARE THERAPY. Journal of Hepatology, 2012, 56, S20.	1.8	0
312	Reply to: "The "pegylated―story continues – Perhaps because both ends (α2a and α2b) are true?― Jo of Hepatology, 2012, 57, 229.	urnal 1.8	0
313	1099 ITPA VARIANTS PREDICT TREATMENT-INDUCED ANEMIA AND THE NEED FOR RIBAVIRIN DOSE REDUCTION AND ERYTHROPOIETIN SUPPORT. Journal of Hepatology, 2012, 56, S432-S433.	1.8	0
314	1008 SUSTAINED VIROLOGIC RESPONSE TO INTERFERON PREVENTS THE LETHAL CONSEQUENCE OF CLINICAL DECOMPENSATION IN PATIENTS WHO DEVELOP A HEPATOCELLULAR CARCINOMA POST ANTIVIRAL-TREATMENT. Journal of Hepatology, 2012, 56, S394.	1.8	0
315	1080 LOW RATES OF SVR TO PEGINTERFERON PLUS RIBAVIRIN IN HCV GENOTYPE 1 IL28B RS12979860 CC CIRRHOTIC PATIENTS WITHOUT RAPID VIROLOGICAL RESPONSE. Journal of Hepatology, 2012, 56, S425.	1.8	0
316	1065 COMBINED TRANSIENT ELASTOGRAPHY OF THE LIVER AND SPLEEN TO ASSESS DISEASE SEVERITY IN CHRONIC VIRAL LIVER DISEASE. Journal of Hepatology, 2012, 56, S419.	1.8	0
317	Insulin Resistance and Response to Telaprevir Plus Pegylated Interferon and Ribavirin: A Requiem for the HOMA Score?. Gastroenterology, 2012, 143, 1685-1687.	0.6	0
318	810 INTERPLAY BETWEEN ON-TREATMENT PREDICTORS AND DONOR/RECIPIENT (D/R) IL28B STATUS IN PREDICTING SUSTAINED VIROLOGICAL RESPONSE (SVR) IN HCV-1,4 LIVER TRANSPLANT (LT) RECIPIENTS TREATED WITH PEG-INTERFERON+ RIBAVIRIN (PR). Journal of Hepatology, 2013, 58, S332.	1.8	0
319	448 IL28B GENOTYPE IS NOT ASSOCIATED WITH INSULIN RESISTANCE IN CHRONIC HEPATITIS C PATIENTS. Journal of Hepatology, 2013, 58, S183.	1.8	0
320	Optimal Management of Hepatitis C Genotype 2 Chronic Infection. Current Hepatology Reports, 2014, 13, 273-278.	0.4	0
321	Hepatitis C Virus. , 2014, , 859-877.		0
322	Inosine triphosphatase deficiency does not predict anemia severity nor anemia management in patients with advanced fibrosis receiving telaprevir. Digestive and Liver Disease, 2014, 46, e20.	0.4	0
323	Peg-interferon and ribavirin therapy is safe and effective among HCV patients with thalassaemia major. Digestive and Liver Disease, 2014, 46, e19.	0.4	0
324	Low accuracy of non-invasive tests for assessing residual cirrhosis in hepatitis C patients with a sustained virological response. Digestive and Liver Disease, 2014, 46, e16.	0.4	0

#	Article	IF	CITATIONS
325	Linkage between interferon-λ4 and IL28B polymorphisms in HCV-4 patients treated with pegylated interferon and ribavirin. Digestive and Liver Disease, 2014, 46, e21.	0.4	0
326	Missense variant in interferon-λ4 gene identifies HCV-1 infected patients carrying the unfavorable IL28B (T) allele with improved viral kinetics. Digestive and Liver Disease, 2014, 46, e22.	0.4	0
327	UPDATED CUT OFF VALUES OF LIVER STIFFNESS TO MAXIMIZE TREATMENT OUTCOME OF INTERFERON FREE ANTI HCV REGIMENS. Digestive and Liver Disease, 2015, 47, e50-e51.	0.4	Ο
328	P0206 : Prevention of bleeding following invasive procedures in cirrhotic patients: A single center experience. Journal of Hepatology, 2015, 62, S383.	1.8	0
329	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. International Journal of Drug Policy, 2015, , 101669.	1.6	0
330	Prevention of bleeding following invasive procedures in cirrhotic patients: A single center experience. Digestive and Liver Disease, 2015, 47, e10.	0.4	0
331	P0751 : Polymorphisms in the FAS promoter region are not associated with fibrosis progression in HCV-1 and -4 patients. Journal of Hepatology, 2015, 62, S610-S611.	1.8	0
332	Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?. Gastroenterology, 2015, 149, 500-501.	0.6	0
333	Genotype 2 Patients: What is the Optimum Therapy so Far?. Current Hepatology Reports, 2015, 14, 253-259.	0.4	0
334	A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure. Digestive and Liver Disease, 2016, 48, e233.	0.4	0
335	Genotype 3 infection in DAA era: Preliminary reports of a real life northern Italy network for viral hepatitis. Digestive and Liver Disease, 2016, 48, e235.	0.4	0
336	TM6SF2 and MBOAT7 genotype to determine alcohol-related liver damage in patients with HCV chronic hepatitis. Digestive and Liver Disease, 2016, 48, e235.	0.4	0
337	The role of serum alphafetoprotein determination in HCV-cirrhosis after antiviral treatment. Digestive and Liver Disease, 2016, 48, e54.	0.4	0
338	ITPA deficiency does not predict anaemia during Ribavirin containing DAA all oral regimens for HCV. Digestive and Liver Disease, 2016, 48, e50.	0.4	0
339	Accuracy of the Radiological Diagnosis of Hepatocellular Carcinoma outside the Periodic Surveillance with Ultrasound. Journal of Hepatology, 2016, 64, S335.	1.8	0
340	Inosine Triphosphatase Deficiency does not Predict Anaemia during Ribavirin Containing DAA All Oral Regimens for HCV. Journal of Hepatology, 2016, 64, S821-S822.	1.8	0
341	Lack of Improvement of Liver Stiffness during Sofosbuvir-Treatment in Decompensated Cirrhotic Patients Listed for Liver Transplant Seems to be Associated with more Severe Histological Damage in the Native Liver. Journal of Hepatology, 2016, 64, S546-S547.	1.8	0
342	Core Antigen Quantification to Monitor Treatment Efficacy in Patients with Chronic Hepatitis C Receiving Directly Acting Antivirals. Journal of Hepatology, 2016, 64, S762.	1.8	0

#	Article	IF	CITATIONS
343	Reply. Hepatology, 2016, 63, 1052-1053.	3.6	0
344	Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy. Digestive and Liver Disease, 2017, 49, e62-e63.	0.4	0
345	Serum markers for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment. Digestive and Liver Disease, 2017, 49, e47.	0.4	0
346	Treatment of chronic hepatitis C: can complexity pave the way towards elimination?. The Lancet Gastroenterology and Hepatology, 2017, 2, 465-466.	3.7	0
347	Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN. Digestive and Liver Disease, 2017, 49, e33-e34.	0.4	0
348	The old patient in DAA era: Real life reports on 5925 patients from the Lombardy HCV Network. Digestive and Liver Disease, 2017, 49, e67-e68.	0.4	0
349	Treatment of chronic hepatitis C in Lombardia: An analysis on the safety and efficacy of DAA therapy in 5457 patients. Digestive and Liver Disease, 2017, 49, e70.	0.4	0
350	Serum Markers for early diagnosis of hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virological response to direct-acting antivirals treatment. Journal of Hepatology, 2017, 66, S209-S210.	1.8	0
351	TM6SF2, MBOAT7 and PNPLA3 genotypes in patients with untreated HCV chronic hepatitis and alcohol intake. Journal of Hepatology, 2017, 66, S500.	1.8	0
352	Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN. Journal of Hepatology, 2017, 66, S733-S734.	1.8	0
353	Incidence and outcome of portal vein thrombosis in HCV cirrhotic patients treated with direct-acting antivirals: A single-center prospective 3-year study. Digestive and Liver Disease, 2018, 50, 30.	0.4	0
354	Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network. Digestive and Liver Disease, 2018, 50, 32.	0.4	0
355	Risk and outcome of hepatitis B virus reactivation during chronic hepatitis C treatment with direct-acting antivirals in patients with HCV-related advanced fibrosis: a single-center experience. Journal of Hepatology, 2018, 68, S265-S266.	1.8	0
356	Impaired renal function but high sustained virological response (SVR) rates in hepatitis C virus (HCV) elderly treated with direct-acting antivirals (DAA): A report from the Lombardy Network. Digestive and Liver Disease, 2018, 50, 13-14.	0.4	0
357	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with direct acting antivirals: A prospective multicenter Italian study. Digestive and Liver Disease, 2018, 50, 34-35.	0.4	0
358	Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment. Digestive and Liver Disease, 2018, 50, 49.	0.4	0
359	Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group. Digestive and Liver Disease, 2018, 50, 52.	0.4	0
360	Excellent effectiveness of direct-acting antivirals for HCV treatment in patients with cirrhosis: Analysis of 3345 patients from the Lombardia Network. Digestive and Liver Disease, 2018, 50, 38.	0.4	0

#	Article	IF	CITATIONS
361	Temporal trends of access to DAAs treatments for HCV in the Navigatore-Lombardia network: Evolution of AIFA criteria, DAA regimens and patient features. Digestive and Liver Disease, 2018, 50, 45-46.	0.4	0
362	12 weeks ombitasvir/paritaprevir–ritonavirâ€~+â€~ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. Digestive and Liver Disease, 2018, 50, 703-706.	0.4	0
363	TLL1 variants do not predict the development of de-novo hepatocellular carcinoma in HCV cirrhotics treated with IFN-free DAA-based regimens. Journal of Hepatology, 2018, 68, S527.	1.8	Ο
364	Incidence and outcome of portal vein thrombosis in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3-year study. Journal of Hepatology, 2018, 68, S258-S259.	1.8	0
365	THU-112-Real-world health care resource utilization and quality of life with G/P treatment: A pooled analysis from post-marketing observational studies. Journal of Hepatology, 2019, 70, e207.	1.8	0
366	THU-398-Circulating HCV resistant strains may result in long-term challenges to HCV elimination: A modeling study. Journal of Hepatology, 2019, 70, e330-e331.	1.8	0
367	THU-128-Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Journal of Hepatology, 2019, 70, e215-e216.	1.8	Ο
368	Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks. Digestive and Liver Disease, 2019, 51, e15.	0.4	0
369	Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients. Digestive and Liver Disease, 2019, 51, e55-e56.	0.4	Ο
370	SAT-493-Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e850-e851.	1.8	0
371	Extra-hepatic tumor recurrence after directly-acting-antiviral (DAA) therapy in HCV patients. Digestive and Liver Disease, 2019, 51, e63.	0.4	Ο
372	Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy. Digestive and Liver Disease, 2019, 51, e16-e17.	0.4	0
373	Editorial: should we abandon HCV genotype testing? Maybe. Alimentary Pharmacology and Therapeutics, 2019, 49, 1097-1098.	1.9	0
374	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Infection, 2019, 47, 141-168.	2.3	0
375	Global characterization of tumor infiltrate of Intrahepatic Cholangiocarcinoma by single cell sequencing. Digestive and Liver Disease, 2020, 52, e48-e49.	0.4	0
376	The metabolic plasticity of neoplastic cholangiocytes: perspective for target therapy of intrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2020, 52, e5.	0.4	0
377	The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated HCV virus infection: An interim analysis in the PITER cohort. Digestive and Liver Disease, 2020, 52, e7.	0.4	0
378	Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications. Digestive and Liver Disease, 2020, 52, e55.	0.4	0

Alessio Aghemo

#	Article	IF	CITATIONS
379	Impact of HBV infection in HCV/HBV coinfected patients treated with DAAs IN Northern Italy. Digestive and Liver Disease, 2020, 52, e19-e20.	0.4	0
380	Directly acting antivirals are safe and effective in HCV elderly patients: a multicenter real life study. Digestive and Liver Disease, 2020, 52, e28.	0.4	0
381	Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?. Lancet Haematology,the, 2021, 8, e8-e10.	2.2	0
382	High prevalence of multiple drug resistant bacterial infections in patients with pyogenic liver abscesses following loco regional therapy for liver cancer. Digestive and Liver Disease, 2021, 53, S21.	0.4	0
383	No impact of the 2020 COVID-19 lockdown on hospitalization rates for alcoholic liver disease in a large tertiary hospital in Milan. Digestive and Liver Disease, 2021, 53, S30.	0.4	0
384	Anemia during Pegylated Interferon-Ribavirin Therapy Results from Both Increase Suppression of Erythroid Differentiation and Hemolysis. Blood, 2008, 112, 4577-4577.	0.6	0
385	In Vitro Effect of Ribavirin and Pegylated Interferon on Erythropoiesis. Blood, 2008, 112, 4786-4786.	0.6	0
386	Diagnostic accuracy and standardization of fine needle biopsy in the characterization of liver nodules in cirrhosis Journal of Clinical Oncology, 2010, 28, e14576-e14576.	0.8	0
387	Natural history and multimodality treatment of early hepatocellular carcinoma prospectively detected in cirrhotic patients under surveillance Journal of Clinical Oncology, 2010, 28, e14574-e14574.	0.8	0
388	The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound Journal of Clinical Oncology, 2010, 28, e14631-e14631.	0.8	0
389	Indolent B-Cell Lymphomas Treated Upfront with Antiviral Therapy: a Series of 13 Patients. Blood, 2010, 116, 2876-2876.	0.6	0
390	Predictors of Sustained Virological Response After Antiviral Therapy for Chronic Hepatitis C In Patients with Hemophilia: The Role of the Interleukin-28B (IL28B) Polymorphism. Blood, 2011, 118, 2276-2276.	0.6	0
391	Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000248.	0.2	0
392	Title is missing!. , 2020, 15, e0232371.		0
393	Title is missing!. , 2020, 15, e0232371.		0
394	Title is missing!. , 2020, 15, e0232371.		0
395	Title is missing!. , 2020, 15, e0232371.		0